Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock News

NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD

21.74  +0.88 (+4.22%)

ADMA Latest News, Press Relases and Analysis

News Image
2 days ago - Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Strong Growth Stock with Technical Breakout Potential

ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.

News Image
4 days ago - Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A High Growth Momentum Stock with Strong Technical Setup

ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout opportunity.

News Image
5 days ago - Zacks Investment Research

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.

Mentions: GRFS TAK

News Image
6 days ago - Zacks Investment Research

Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar?

Style Box ETF report for XSHQ

Mentions: IVZ AWI CORT

News Image
8 days ago - Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock

ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech sector.

News Image
14 days ago - Zacks Investment Research

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

Mentions: GRFS

News Image
20 days ago - Zacks Investment Research

Are Options Traders Betting on a Big Move in ADMA Biologics Stock?

Investors need to pay close attention to ADMA Biologics stock based on the movements in the options market lately.

News Image
a month ago - Zacks Investment Research

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

Mentions: SNY BEAM KYMR

News Image
a month ago - Zacks Investment Research

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

Mentions: BEAM PCRX

News Image
a month ago - Zacks Investment Research

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.

Mentions: BEAM RCKT

News Image
a month ago - Zacks Investment Research

PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates

Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading

Mentions: PBYI ANIP IMCR

News Image
a month ago - Zacks Investment Research

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.

Mentions: GRFS TAK

News Image
a month ago - Zacks Investment Research

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.

Mentions: BEAM VTRS

News Image
a month ago - Investor's Business Daily

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits

The company makes immunoglobulin products using donated plasma.

Mentions: HIMS

News Image
a month ago - Zacks Investment Research

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

Mentions: BEAM CPRX

News Image
a month ago - Zacks Investment Research

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.

Mentions: BEAM APLS

News Image
a month ago - Zacks Investment Research

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Mentions: BEAM ACAD

News Image
a month ago - Zacks Investment Research

Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: BHST

News Image
a month ago - ADMA Biologics, Inc.

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51%...

News Image
a month ago - Zacks Investment Research

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.

Mentions: BEAM KRYS

News Image
a month ago - Zacks Investment Research

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.

Mentions: CORT IMCR

News Image
a month ago - MarketBeat

3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

Mentions: TMDX PEN

News Image
a month ago - Zacks Investment Research

VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened

Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.

Mentions: VRTX CRSP IMCR

News Image
a month ago - Zacks Investment Research

Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised

ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.

Mentions: BEAM ZTS

News Image
a month ago - Zacks Investment Research

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Mentions: JAZZ AXSM IMCR

News Image
a month ago - Zacks Investment Research

RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates

Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.

Mentions: BEAM RXRX

News Image
a month ago - Zacks Investment Research

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

Mentions: BEAM AGIO IMCR

News Image
a month ago - Zacks Investment Research

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?

Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.

Mentions: GRFS TAK

News Image
a month ago - Zacks Investment Research

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

Mentions: BEAM MDGL

News Image
a month ago - Zacks Investment Research

Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down

BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.

Mentions: BEAM FOLD BHC

News Image
a month ago - Zacks Investment Research

Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Mentions: AGL

News Image
a month ago - Zacks Investment Research

Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know

Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.